Global Retinal Biologics Market Size Study & Forecast, by Drug Class (VEGF-A Antagonist, TNF-a Inhibitor), by Disease Indication (Macular Degeneration, Diabetic Retinopathy, Uveitis, Other Disease Indications), and Regional Analysis, 2023-2030
Global Retinal Biologics Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.8% during the forecast period 2023-2030. Retinal biologics are specialized treatments for retinal diseases that employ biological substances such as proteins, antibodies, gene therapy, or cell-based therapies. These innovative therapies target specific pathways involved in conditions such as age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion Derived from living organisms such as proteins or antibodies, these biologics are meticulously designed to target precise molecules or processes implicated in retinal diseases. By homing in on the underlying mechanisms, they offer targeted therapies that surpass conventional approaches in efficacy. Administered primarily through intravitreal injections, the delivery method ensures direct application of the medication into the eye, optimizing treatment precision and efficacy. The Retinal Biologics Market is expanding because of factors such as the rising number of FDA approvals, increasing healthcare expenditure, coupled with the growing aging population. The Retinal Biologics Market is poised for growth due to the introduction of diverse drug products aimed at treating retinal diseases, which is fostering increased competition in the market.
In addition, the prevalence of vision impairments, including diabetic retinopathy is to further stimulate market demand across the globe. According to a 2023 report by the World Health Organization (WHO), approximately 2.2 billion individuals globally are affected by either distant or near vision impairments, underscoring the urgent need for effective treatments in the retinal biologics market. Also, according to the study conducted by National Institute of Health (NIH) titled 'Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis,' published in November 2021, the global prevalence of diabetic retinopathy among adults stood at an estimated 103.12 million in 2020. Projections suggest that by 2045, this figure rise substantially to reach 160.50 million individuals. This escalation in the prevalence of retinal diseases or diabetic retinopathy is anticipated to fuel demand for biological treatments, consequently propelling the growth of the Retinal Biologics Market during the estimated period of 2023-2030. Moreover, the rising innovation in biotechnology and drug development, as well as the growing investment in research and development present various lucrative opportunities over the forecast years. However, the high initial capital investment and stringent regulatory process are challenging the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Retinal Biologics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing R&D activities and the growing number of FDA approvals. The market in this region is expected to witness further growth, supported by the presence of major players. Moreover, key stakeholders in the region are implementing various strategies such as acquisitions, product launches, and partnerships to fortify their positions. For instance, in June 2020, Novartis announced the U.S. FDA's approval for a label update for Beovu, which includes the addition of a subsection dedicated to retinal vasculitis or retinal vascular occlusion under 'Warnings and Precautions'. Similarly in September 2021, the U.S. FDA approved the first biosimilar, Byooviz, for the treatment of macular degeneration disease. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increasing prevalence of retinal diseases, the growing burden of the diabetic population, as well as advancements in biotechnology and drug development, are significantly propelling the market demand across the region.
Major market players included in this report are:
F. Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals Inc.
AbbVie Inc.
MeiraGTx Limited
Oxurion NV
Novartis AG
GenSight Biologics S.A.
Adverum Biotechnologies Inc
SemaThera Inc.
Amgen Inc.
Recent Developments in the Market:
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
VEGF-A Antagonist
TNF-a Inhibitor
By Disease Indication:
Macular Degeneration
Diabetic Retinopathy
Uveitis
Other Disease Indications
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
In addition, the prevalence of vision impairments, including diabetic retinopathy is to further stimulate market demand across the globe. According to a 2023 report by the World Health Organization (WHO), approximately 2.2 billion individuals globally are affected by either distant or near vision impairments, underscoring the urgent need for effective treatments in the retinal biologics market. Also, according to the study conducted by National Institute of Health (NIH) titled 'Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis,' published in November 2021, the global prevalence of diabetic retinopathy among adults stood at an estimated 103.12 million in 2020. Projections suggest that by 2045, this figure rise substantially to reach 160.50 million individuals. This escalation in the prevalence of retinal diseases or diabetic retinopathy is anticipated to fuel demand for biological treatments, consequently propelling the growth of the Retinal Biologics Market during the estimated period of 2023-2030. Moreover, the rising innovation in biotechnology and drug development, as well as the growing investment in research and development present various lucrative opportunities over the forecast years. However, the high initial capital investment and stringent regulatory process are challenging the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Retinal Biologics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing R&D activities and the growing number of FDA approvals. The market in this region is expected to witness further growth, supported by the presence of major players. Moreover, key stakeholders in the region are implementing various strategies such as acquisitions, product launches, and partnerships to fortify their positions. For instance, in June 2020, Novartis announced the U.S. FDA's approval for a label update for Beovu, which includes the addition of a subsection dedicated to retinal vasculitis or retinal vascular occlusion under 'Warnings and Precautions'. Similarly in September 2021, the U.S. FDA approved the first biosimilar, Byooviz, for the treatment of macular degeneration disease. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increasing prevalence of retinal diseases, the growing burden of the diabetic population, as well as advancements in biotechnology and drug development, are significantly propelling the market demand across the region.
Major market players included in this report are:
F. Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals Inc.
AbbVie Inc.
MeiraGTx Limited
Oxurion NV
Novartis AG
GenSight Biologics S.A.
Adverum Biotechnologies Inc
SemaThera Inc.
Amgen Inc.
Recent Developments in the Market:
- In August 2023, Regeneron Pharmaceuticals, Inc. received approval from the U.S. FDA for an EYLEA HD injection. This approval encompasses its application in treating conditions such as diabetic retinopathy, wet age-related macular degeneration, and diabetic macular edema.
- In March 2023, Praetego Inc. secured funding of USD 300 million from the National Eye Institute. This financial support aims to propel the development of pioneering oral medications designed specifically for diabetic retinopathy.
- In April 2022, Shilpa Biologicals (SBPL) obtained a No Objection Certificate (NoC) from RCGM, Department of Biotechnology, enabling it to approach the Drugs Controller General of India (DCGI) to conduct clinical studies for its Biosimilar Aflibercept. This initiative targets the markets for Wet Age-Related Macular Degeneration (wAMD), Diabetic Retinopathy, Diabetic Macular Edema (DME), and Macular Edema following Retinal Vein Occlusion, both in India and globally.
- Historical Data – 2020 - 2021
- Base Year for Estimation – 2022
- Forecast period - 2023-2030
- Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered - Drug Class, Disease Indication, Region
- Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
- Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
VEGF-A Antagonist
TNF-a Inhibitor
By Disease Indication:
Macular Degeneration
Diabetic Retinopathy
Uveitis
Other Disease Indications
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Retinal Biologics Market, by Region, 2020-2030 (USD Billion)
1.2.2. Retinal Biologics Market, by Drug Class, 2020-2030 (USD Billion)
1.2.3. Retinal Biologics Market, by Disease Indication, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL RETINAL BIOLOGICS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL RETINAL BIOLOGICS MARKET DYNAMICS
3.1. Retinal Biologics Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increasing introduction of diverse drug products
3.1.1.2. Rising prevalence of vision impairments
3.1.2. Market Challenges
3.1.2.1. High initial capital investment
3.1.2.2. Stringent regulatory process
3.1.3. Market Opportunities
3.1.3.1. Rising innovation in biotechnology and drug development
3.1.3.2. Growing investment in research and development
CHAPTER 4. GLOBAL RETINAL BIOLOGICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL RETINAL BIOLOGICS MARKET, BY DRUG CLASS
5.1. Market Snapshot
5.2. Global Retinal Biologics Market by Drug Class, Performance - Potential Analysis
5.3. Global Retinal Biologics Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
5.4. Retinal Biologics Market, Sub Segment Analysis
5.4.1. VEGF-A Antagonist
5.4.2. TNF-a Inhibitor
CHAPTER 6. GLOBAL RETINAL BIOLOGICS MARKET, BY DISEASE INDICATION
6.1. Market Snapshot
6.2. Global Retinal Biologics Market by Disease Indication, Performance - Potential Analysis
6.3. Global Retinal Biologics Market Estimates & Forecasts by Disease Indication 2020-2030 (USD Billion)
6.4. Retinal Biologics Market, Sub Segment Analysis
6.4.1. Macular Degeneration
6.4.2. Diabetic Retinopathy
6.4.3. Uveitis
6.4.4. Other Disease Indications
CHAPTER 7. GLOBAL RETINAL BIOLOGICS MARKET, REGIONAL ANALYSIS
7.1. Top Leading Countries
7.2. Top Emerging Countries
7.3. Retinal Biologics Market, Regional Market Snapshot
7.4. North America Retinal Biologics Market
7.4.1. U.S. Retinal Biologics Market
7.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
7.4.1.2. Disease Indication breakdown estimates & forecasts, 2020-2030
7.4.2. Canada Retinal Biologics Market
7.5. Europe Retinal Biologics Market Snapshot
7.5.1. U.K. Retinal Biologics Market
7.5.2. Germany Retinal Biologics Market
7.5.3. France Retinal Biologics Market
7.5.4. Spain Retinal Biologics Market
7.5.5. Italy Retinal Biologics Market
7.5.6. Rest of Europe Retinal Biologics Market
7.6. Asia-Pacific Retinal Biologics Market Snapshot
7.6.1. China Retinal Biologics Market
7.6.2. India Retinal Biologics Market
7.6.3. Japan Retinal Biologics Market
7.6.4. Australia Retinal Biologics Market
7.6.5. South Korea Retinal Biologics Market
7.6.6. Rest of Asia Pacific Retinal Biologics Market
7.7. Latin America Retinal Biologics Market Snapshot
7.7.1. Brazil Retinal Biologics Market
7.7.2. Mexico Retinal Biologics Market
7.8. Middle East & Africa Retinal Biologics Market
7.8.1. Saudi Arabia Retinal Biologics Market
7.8.2. South Africa Retinal Biologics Market
7.8.3. Rest of Middle East & Africa Retinal Biologics Market
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Key Company SWOT Analysis
8.1.1. Company
8.1.2. Company
8.1.3. Company
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. F. Hoffmann-La Roche Ltd
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Recent Developments
8.3.2. Regeneron Pharmaceuticals Inc.
8.3.3. AbbVie Inc.
8.3.4. MeiraGTx Limited
8.3.5. Oxurion NV
8.3.6. Novartis AG
8.3.7. GenSight Biologics S.A.
8.3.8. Adverum Biotechnologies Inc
8.3.9. SemaThera Inc.
8.3.10. Amgen Inc.
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Retinal Biologics Market, by Region, 2020-2030 (USD Billion)
1.2.2. Retinal Biologics Market, by Drug Class, 2020-2030 (USD Billion)
1.2.3. Retinal Biologics Market, by Disease Indication, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL RETINAL BIOLOGICS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL RETINAL BIOLOGICS MARKET DYNAMICS
3.1. Retinal Biologics Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increasing introduction of diverse drug products
3.1.1.2. Rising prevalence of vision impairments
3.1.2. Market Challenges
3.1.2.1. High initial capital investment
3.1.2.2. Stringent regulatory process
3.1.3. Market Opportunities
3.1.3.1. Rising innovation in biotechnology and drug development
3.1.3.2. Growing investment in research and development
CHAPTER 4. GLOBAL RETINAL BIOLOGICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL RETINAL BIOLOGICS MARKET, BY DRUG CLASS
5.1. Market Snapshot
5.2. Global Retinal Biologics Market by Drug Class, Performance - Potential Analysis
5.3. Global Retinal Biologics Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
5.4. Retinal Biologics Market, Sub Segment Analysis
5.4.1. VEGF-A Antagonist
5.4.2. TNF-a Inhibitor
CHAPTER 6. GLOBAL RETINAL BIOLOGICS MARKET, BY DISEASE INDICATION
6.1. Market Snapshot
6.2. Global Retinal Biologics Market by Disease Indication, Performance - Potential Analysis
6.3. Global Retinal Biologics Market Estimates & Forecasts by Disease Indication 2020-2030 (USD Billion)
6.4. Retinal Biologics Market, Sub Segment Analysis
6.4.1. Macular Degeneration
6.4.2. Diabetic Retinopathy
6.4.3. Uveitis
6.4.4. Other Disease Indications
CHAPTER 7. GLOBAL RETINAL BIOLOGICS MARKET, REGIONAL ANALYSIS
7.1. Top Leading Countries
7.2. Top Emerging Countries
7.3. Retinal Biologics Market, Regional Market Snapshot
7.4. North America Retinal Biologics Market
7.4.1. U.S. Retinal Biologics Market
7.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
7.4.1.2. Disease Indication breakdown estimates & forecasts, 2020-2030
7.4.2. Canada Retinal Biologics Market
7.5. Europe Retinal Biologics Market Snapshot
7.5.1. U.K. Retinal Biologics Market
7.5.2. Germany Retinal Biologics Market
7.5.3. France Retinal Biologics Market
7.5.4. Spain Retinal Biologics Market
7.5.5. Italy Retinal Biologics Market
7.5.6. Rest of Europe Retinal Biologics Market
7.6. Asia-Pacific Retinal Biologics Market Snapshot
7.6.1. China Retinal Biologics Market
7.6.2. India Retinal Biologics Market
7.6.3. Japan Retinal Biologics Market
7.6.4. Australia Retinal Biologics Market
7.6.5. South Korea Retinal Biologics Market
7.6.6. Rest of Asia Pacific Retinal Biologics Market
7.7. Latin America Retinal Biologics Market Snapshot
7.7.1. Brazil Retinal Biologics Market
7.7.2. Mexico Retinal Biologics Market
7.8. Middle East & Africa Retinal Biologics Market
7.8.1. Saudi Arabia Retinal Biologics Market
7.8.2. South Africa Retinal Biologics Market
7.8.3. Rest of Middle East & Africa Retinal Biologics Market
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Key Company SWOT Analysis
8.1.1. Company
8.1.2. Company
8.1.3. Company
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. F. Hoffmann-La Roche Ltd
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Recent Developments
8.3.2. Regeneron Pharmaceuticals Inc.
8.3.3. AbbVie Inc.
8.3.4. MeiraGTx Limited
8.3.5. Oxurion NV
8.3.6. Novartis AG
8.3.7. GenSight Biologics S.A.
8.3.8. Adverum Biotechnologies Inc
8.3.9. SemaThera Inc.
8.3.10. Amgen Inc.
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption
LIST OF TABLES
TABLE 1. Global Retinal Biologics Market, report scope
TABLE 2. Global Retinal Biologics Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Retinal Biologics Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
TABLE 4. Global Retinal Biologics Market estimates & forecasts by Disease Indication 2020-2030 (USD Billion)
TABLE 5. Global Retinal Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 6. Global Retinal Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Retinal Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Retinal Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Retinal Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Retinal Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Retinal Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Retinal Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Retinal Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Retinal Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. U.S. Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 17. U.S. Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. Canada Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 19. Canada Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 20. Canada Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 21. UK Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 22. UK Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 23. UK Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 24. Germany Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 25. Germany Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 26. Germany Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 27. France Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 28. France Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 29. France Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 30. Italy Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 31. Italy Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 32. Italy Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 33. Spain Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 34. Spain Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 35. Spain Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 36. RoE Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 37. RoE Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 38. RoE Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 39. China Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 40. China Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 41. China Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 42. India Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 43. India Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 44. India Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 45. Japan Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 46. Japan Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 47. Japan Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 48. South Korea Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 49. South Korea Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 50. South Korea Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 51. Australia Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 52. Australia Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 53. Australia Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 54. RoAPAC Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 55. RoAPAC Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 56. RoAPAC Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 57. Brazil Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 58. Brazil Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 59. Brazil Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 60. Mexico Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 61. Mexico Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 62. Mexico Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 63. RoLA Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 64. RoLA Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 65. RoLA Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 66. Saudi Arabia Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 67. South Africa Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 68. RoMEA Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 69. List of secondary sources, used in the study of global Retinal Biologics Market
TABLE 70. List of primary sources, used in the study of global Retinal Biologics Market
TABLE 71. Years considered for the study
TABLE 72. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
TABLE 1. Global Retinal Biologics Market, report scope
TABLE 2. Global Retinal Biologics Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Retinal Biologics Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
TABLE 4. Global Retinal Biologics Market estimates & forecasts by Disease Indication 2020-2030 (USD Billion)
TABLE 5. Global Retinal Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 6. Global Retinal Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Retinal Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Retinal Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Retinal Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Retinal Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Retinal Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Retinal Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Retinal Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Retinal Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. U.S. Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 17. U.S. Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. Canada Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 19. Canada Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 20. Canada Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 21. UK Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 22. UK Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 23. UK Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 24. Germany Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 25. Germany Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 26. Germany Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 27. France Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 28. France Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 29. France Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 30. Italy Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 31. Italy Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 32. Italy Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 33. Spain Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 34. Spain Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 35. Spain Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 36. RoE Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 37. RoE Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 38. RoE Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 39. China Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 40. China Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 41. China Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 42. India Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 43. India Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 44. India Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 45. Japan Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 46. Japan Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 47. Japan Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 48. South Korea Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 49. South Korea Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 50. South Korea Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 51. Australia Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 52. Australia Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 53. Australia Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 54. RoAPAC Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 55. RoAPAC Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 56. RoAPAC Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 57. Brazil Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 58. Brazil Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 59. Brazil Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 60. Mexico Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 61. Mexico Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 62. Mexico Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 63. RoLA Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 64. RoLA Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 65. RoLA Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 66. Saudi Arabia Retinal Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 67. South Africa Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 68. RoMEA Retinal Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 69. List of secondary sources, used in the study of global Retinal Biologics Market
TABLE 70. List of primary sources, used in the study of global Retinal Biologics Market
TABLE 71. Years considered for the study
TABLE 72. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
LIST OF FIGURES
FIG 1. Global Retinal Biologics Market, research methodology
FIG 2. Global Retinal Biologics Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Retinal Biologics Market, key trends 2022
FIG 5. Global Retinal Biologics Market, growth prospects 2023-2030
FIG 6. Global Retinal Biologics Market, porters 5 force model
FIG 7. Global Retinal Biologics Market, pest analysis
FIG 8. Global Retinal Biologics Market, value chain analysis
FIG 9. Global Retinal Biologics Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Retinal Biologics Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Retinal Biologics Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Retinal Biologics Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Retinal Biologics Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Retinal Biologics Market, regional snapshot 2020 & 2030
FIG 15. North America Retinal Biologics Market 2020 & 2030 (USD Billion)
FIG 16. Europe Retinal Biologics Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Retinal Biologics Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Retinal Biologics Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Retinal Biologics Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
FIG 1. Global Retinal Biologics Market, research methodology
FIG 2. Global Retinal Biologics Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Retinal Biologics Market, key trends 2022
FIG 5. Global Retinal Biologics Market, growth prospects 2023-2030
FIG 6. Global Retinal Biologics Market, porters 5 force model
FIG 7. Global Retinal Biologics Market, pest analysis
FIG 8. Global Retinal Biologics Market, value chain analysis
FIG 9. Global Retinal Biologics Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Retinal Biologics Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Retinal Biologics Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Retinal Biologics Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Retinal Biologics Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Retinal Biologics Market, regional snapshot 2020 & 2030
FIG 15. North America Retinal Biologics Market 2020 & 2030 (USD Billion)
FIG 16. Europe Retinal Biologics Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Retinal Biologics Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Retinal Biologics Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Retinal Biologics Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
